Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07676266
What this trial is testing

C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Who this might be right for
Multiple Sclerosis (MS)Myasthenia Gravis (MG)Neuromyelitis Optica Spectrum Disorder+3 more
The Affiliated Hospital of Qingdao University 18
Testing effectiveness (Phase 2)Ended earlyNCT01874288
What this trial is testing

De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

Who this might be right for
B-cell Non-Hodgkin Lymphoma
Alopexx Oncology, LLC 24
Not applicableStudy completedNCT05712369
What this trial is testing

B Cells in Idiopathic Nephrotic Syndrome

Who this might be right for
Nephrotic Syndrome
Mario Negri Institute for Pharmacological Research 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT01059786
What this trial is testing

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Who this might be right for
Hairy Cell Leukemia
National Cancer Institute (NCI) 69
Testing effectiveness (Phase 2)WithdrawnNCT06153095
What this trial is testing

IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Who this might be right for
Systemic Lupus ErythematosusLupus Nephritis
Lyell Immunopharma, Inc.
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Early research (Phase 1)Study completedNCT04599634
What this trial is testing

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma+2 more
National Cancer Institute (NCI) 11
Early research (Phase 1)Ended earlyNCT05318963
What this trial is testing

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Institute of Hematology & Blood Diseases Hospital, China 14
Large-scale testing (Phase 3)Study completedNCT02406092
What this trial is testing

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Who this might be right for
Non-Hodgkin Lymphoma
Hoffmann-La Roche 139
Testing effectiveness (Phase 2)Active Not RecruitingNCT07480863
What this trial is testing

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Who this might be right for
Marginal Zone Lymphoma(MZL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 65
Testing effectiveness (Phase 2)Study completedNCT00073931
What this trial is testing

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Fred Hutchinson Cancer Center 25
Early research (Phase 1)UnknownNCT04486872
What this trial is testing

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Who this might be right for
Diffuse Large B Cell Lymphoma
First Affiliated Hospital of Zhejiang University 18
Testing effectiveness (Phase 2)Study completedNCT00379431
What this trial is testing

A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

Who this might be right for
Early and Severe Systemic Sclerosis
University Hospital, Ghent 9
Testing effectiveness (Phase 2)Looking for participantsNCT05800977
What this trial is testing

C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd. 112
Testing effectiveness (Phase 2)Looking for participantsNCT04523428
What this trial is testing

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Who this might be right for
CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland 60
Early research (Phase 1)Ended earlyNCT03189836
What this trial is testing

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Who this might be right for
Lymphoma
Cogent Biosciences, Inc. 26
Testing effectiveness (Phase 2)WithdrawnNCT03232307
What this trial is testing

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Who this might be right for
CCND1 PositiveCD20-Positive Neoplastic Cells PresentMantle Cell Lymphoma
M.D. Anderson Cancer Center
Very early researchEnded earlyNCT06462144
What this trial is testing

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

Who this might be right for
Systemic Lupus Erythematosus (SLE)ANCA Associated Vasculitis (AAV)Idiopathic Inflammatory Myopathy (IIM)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 3
Testing effectiveness (Phase 2)Study completedNCT00169195
What this trial is testing

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Who this might be right for
Diffuse Large Cell Lymphoma
Lymphoma Study Association 49
Post-approval studies (Phase 4)Looking for participantsNCT06529406
What this trial is testing

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Who this might be right for
Relapsing Multiple Sclerosis
University of Colorado, Denver 100
Next Page